Ad disclosure
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Health & pharmaceuticals news
Latest breaking stories, features and analysis
Deutsche Bank: Moderna shares could slide sharply to $250
- Deutsche Bank initiates Moderna with a "sell" rating with a price target of $250.
- Analyst Papadakis says the firm has bleak prospects in the post-pandemic world.
- Shares of the biotech firm are down more than 30% from their year-to-date high.
October 22, 2021
Trending news
